Page last updated: 2024-12-04

cl 387785

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CL 387785: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide : A member of the class of quinazolines that is 4,6-diaminoquinazoine in which the one of the hydrogens attached to the amino group at position 4 has been replaced by a m-bromophenyl group while one of the hydrogens attached to the amino group at position 6 has been replaced by a but-2-ynoyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2776
CHEMBL ID91867
CHEBI ID90180
SCHEMBL ID412104
MeSH IDM0302685

Synonyms (58)

Synonym
chebi:90180 ,
4-anilinoquinazoline deriv. 1
n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide
chembl91867 ,
bdbm4566
BRD-K65674950-001-01-7
HSCI1_000126
eki-785
n-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide
cl-387,785
cl-387785
n-[4-(3-bromoanilino)quinazolin-6-yl]but-2-ynamide
S7557
253310-44-0
cl-387785(eki785; way-eki 785)
CS-3291
HY-10325
SCHEMBL412104
ekb-785
n-(4-((3-bromophenyl)amino)-6-quinazolinyl)-2-butynamide
eki 785
unii-b4w27j1z8b
b4w27j1z8b ,
cl 387785
2-butynamide, n-(4-((3-bromophenyl)amino)-6-quinazolinyl)-
194423-06-8
way-eki-785
n-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide
BTYYWOYVBXILOJ-UHFFFAOYSA-N
n-[4-[(3-bromophenyl)amino]quinazolin-6-yl]but-2-ynamide
n-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide
cl-387785 (eki-785)
n-{4-[(m-bromophenyl)amino]-6-quinazolinyl}-2-butynamide
n-{4-[(m-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide
n-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide
AC-33038
AKOS026674120
J-690255
EX-A578
cl387785
way-eki 785
mfcd02179194
NCGC00386435-04
cl-387
2-butynamide,n-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-
Q27162381
cl-387,785 - cas 194423-06-8
FT-0700252
AS-16651
BCP10214
A13146
SB19359
cl-38875
CCG-268418
NCGC00481562-01
2-butynamide, n-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-
C3575
DTXSID401236539

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
epidermal growth factor receptor antagonistAn antagonist at the epidermal growth factor receptor.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitorAn EC 2.7.10.* (protein-tyrosine kinase) inhibitor that interferes with the action of receptor protein-tyrosine kinase (EC 2.7.10.1).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
quinazolinesAny organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.
ynamideAn alpha,beta-unsaturated monocarboxylic acid amide of general formula R(1)C#C-C(=O)NR(2)R(3) in which the amide C=O function is conjugated to a C#C triple bond at the alpha,beta position.
bromobenzenesA member of the class of benzenes that is benzene substituted by at least one bromo group.
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.69330.01237.983543.2770AID1645841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)IC50 (µMol)13.50050.00040.91515.1000AID719906; AID719907
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)0.04560.00000.536910.0000AID1244850; AID1795646; AID260895; AID260898; AID345876; AID69422; AID719885; AID719886
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)IC50 (µMol)0.19520.00010.545310.0000AID1795646; AID260896; AID69714
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)IC50 (µMol)0.01200.00010.17362.5900AID260897
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)0.20000.00401.966610.0000AID678801
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Epidermal growth factor receptorHomo sapiens (human)EC50 (µMol)0.45000.00200.99027.9300AID383069; AID383070; AID383071
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (160)

Processvia Protein(s)Taxonomy
regulation of cell cycleProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
negative regulation of extrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
protein phosphorylationProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
epidermal growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
cell differentiationProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
cell adhesionProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
negative regulation of intrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
progesterone receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
innate immune responseProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junction developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
motor neuron axon guidanceReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
Schwann cell developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell growthReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of microtubule-based processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of Rho protein signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
intracellular signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-EGFR signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
wound healingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelinationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAP kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of translationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of angiogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell adhesionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
oligodendrocyte differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of epithelial cell proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to epidermal growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
semaphorin-plexin signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein targeting to membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAPK cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuron differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neural crest cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of protein phosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nervous system developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
synapse assemblyReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
lactationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
negative regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
embryonic pattern specificationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
central nervous system morphogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
olfactory bulb interneuron differentiationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
regulation of cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB2-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB4-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrial fragmentation involved in apoptotic processReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell fate commitmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of DNA-templated transcriptionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein autophosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mammary gland epithelial cell differentiationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mammary gland alveolus developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cardiac muscle tissue regenerationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cellular response to epidermal growth factor stimulusReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
establishment of planar polarity involved in nephron morphogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of protein localization to cell surfaceReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (49)

Processvia Protein(s)Taxonomy
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
protein bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
ATP bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
protein phosphatase bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
heme bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
connexin bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
signaling receptor bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
growth factor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
RNA polymerase I core bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane signaling receptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signaling receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
coreceptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor tyrosine kinase bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
identical protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ErbB-3 class receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein heterodimerization activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transcription cis-regulatory region bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neuregulin receptor activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein homodimerization activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
GABA receptor bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (46)

Processvia Protein(s)Taxonomy
cytosolProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
nucleusProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
mitochondrial inner membraneProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
cytoskeletonProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
plasma membraneProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
focal adhesionProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
endosome membraneProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
membraneProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
cell junctionProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
perinuclear region of cytoplasmProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
protein-containing complexProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
plasma membraneProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
semaphorin receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
early endosomeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cytosolReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
endosome membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
apical plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junctionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ruffle membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
presynaptic membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelin sheathReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
perinuclear region of cytoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB3:ERBB2 complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
extracellular regionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleusReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleoplasmReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrial matrixReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cytosolReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neuromuscular junctionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
presynaptic membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
postsynaptic membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
postsynaptic density membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
glutamatergic synapseReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
GABA-ergic synapseReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (282)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID384882Cytotoxicity against human KYSE140 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384195Cytotoxicity against human NCI-H322 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384642Cytotoxicity against human NCI-H1437 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384885Cytotoxicity against human KYSE220 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384391Cytotoxicity against human Panc04.03 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383873Cytotoxicity against human EVSA-T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383865Cytotoxicity against human EFM19 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384851Cytotoxicity against human IM95 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383895Cytotoxicity against human HBE4-E6E7 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384190Cytotoxicity against human NCI-H2342 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384626Cytotoxicity against human MIA PaCa-2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383590Cytotoxicity against human BEN cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384441Cytotoxicity against human MDA-MB-157 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384404Cytotoxicity against human QGP1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383614Cytotoxicity against human CAL51 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383578Cytotoxicity against human A431 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383645Cytotoxicity against human COLO 699 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383867Cytotoxicity against human EFM-192B cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384627Cytotoxicity against human MKN1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID719907Inhibition of chicken c-Src T338G mutant2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Irreversible protein kinase inhibitors: balancing the benefits and risks.
AID384424Cytotoxicity against human LOU-NH91 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384628Cytotoxicity against human MKN28 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383622Cytotoxicity against human CaR1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384180Cytotoxicity against human VMRC-LCP cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384396Cytotoxicity against human PA-TU-8988S cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384891Cytotoxicity against human KYSE510 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384431Cytotoxicity against human LU99B cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383650Cytotoxicity against human COR-L 23/CPR cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID678801TP_TRANSPORTER: efflux of Hoechst33342 in BCRP-expressing Sf9 cells2004Molecular pharmacology, Jun, Volume: 65, Issue:6
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.
AID384640Cytotoxicity against human NCI-H1299 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383927Cytotoxicity against human SEG1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383937Cytotoxicity against human SK-LU-1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384376Cytotoxicity against human OE21 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383070Inhibition of EGFR L858R mutant by cellular assay2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID260895Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
AID384908Cytotoxicity against human WM278 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384686Cytotoxicity against human Hs 707(A).T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383863Cytotoxicity against human DV 90 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID719886Inhibition of EGF-induced autophosphorylation of EGFR in human A431 cells2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Irreversible protein kinase inhibitors: balancing the benefits and risks.
AID383880Cytotoxicity against human G-292 Clone A141B1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384883Cytotoxicity against human KYSE150 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383903Cytotoxicity against human HCC38 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384393Cytotoxicity against human Panc10.05 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383872Cytotoxicity against human EPLC-272H cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384165Cytotoxicity against human TASK1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384182Cytotoxicity against human NCI-H2122 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID719906Inhibition of chicken c-Src2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Irreversible protein kinase inhibitors: balancing the benefits and risks.
AID384400Cytotoxicity against human PC-3[JPC-3] cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384658Cytotoxicity against human NCI-H1869 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384687Cytotoxicity against human Hs 746T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383911Cytotoxicity against human HCT8 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384369Cytotoxicity against human NUGC2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383912Cytotoxicity against human HDQ-P1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383603Cytotoxicity against human C32 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383069Inhibition of EGFR by cellular assay2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384397Cytotoxicity against human PA-TU-8988T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383888Cytotoxicity against human GP5d cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384370Cytotoxicity against human NUGC3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384907Cytotoxicity against human WM 1552C cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384854Cytotoxicity against human IPC298 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384401Cytotoxicity against human PC-9 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384893Cytotoxicity against human KYSE70 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384201Cytotoxicity against human NCI-H596 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID69422Inhibition of epidermal growth factor receptor using enzyme assay2001Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
AID384874Cytotoxicity against human KP-1N cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384402Cytotoxicity against human PL45 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1752680Antischistosomal activity against Schistosoma mansoni infected in NMRI mouse assessed as worm burden reduction at 200 mg/kg, po administered as single dose measured after 16 to 18 days2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID383879Cytotoxicity against human TMK1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384197Cytotoxicity against human NCI-H441 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384631Cytotoxicity against human MKN74 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384659Cytotoxicity against human NCI-H1915 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383598Cytotoxicity against human BT549 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383618Cytotoxicity against human Calu1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384652Cytotoxicity against human NCI-H1703 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384655Cytotoxicity against human NCI-H1781 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384184Cytotoxicity against human NCI-H2170 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384198Cytotoxicity against human NCI-H460 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384179Cytotoxicity against human VMRC-LCD cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384890Cytotoxicity against human KYSE50 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384880Cytotoxicity against human KPL1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384846Cytotoxicity against human IGR1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384374Cytotoxicity against human OCUM1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384896Cytotoxicity against human LCLC-97TM1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384407Cytotoxicity against human RERF-LC-Ad1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383878Cytotoxicity against human FU97 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383644Cytotoxicity against human COLO 680N cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384421Cytotoxicity against human Saos-2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384429Cytotoxicity against human Lu135 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384428Cytotoxicity against human Lu-134-A-H cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384371Cytotoxicity against human NUGC4 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383896Cytotoxicity against human HBE4-E6E7-C1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384897Cytotoxicity against human LK2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383885Cytotoxicity against human GCT cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384148Cytotoxicity against human SW1990 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID260897Inhibition of erbB4 fusion protein expressed in baculovirus by ELISA2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
AID383921Cytotoxicity against human SBC3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384656Cytotoxicity against human NCI-H1792 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384188Cytotoxicity against human NCI-H2286 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384192Cytotoxicity against human NCI-H2405 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384203Cytotoxicity against human NCI-H647 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID260896Inhibition of erbB2 fusion protein expressed in baculovirus by ELISA2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
AID384443Cytotoxicity against human MDA-MB-361 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384671Cytotoxicity against human HGC27 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384653Cytotoxicity against human NCI-H1734 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383864Cytotoxicity against human EBC1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383617Cytotoxicity against human CAL-85-1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384910Cytotoxicity against human WM793b cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384668Cytotoxicity against human NCI-H2085 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384206Cytotoxicity against human NCI-H810 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID770073Half life in phosphate buffer at pH 7.4 at 50 uM by LC-MS analysis in presence of glutathione2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
AID384625Cytotoxicity against human MG63 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384410Cytotoxicity against human RERF-LC-MS cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384660Cytotoxicity against human NCI-H1944 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384139Cytotoxicity against human SW1088 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384903Cytotoxicity against human WI-26 VA4 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383621Cytotoxicity against human Capan2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383387Cytotoxicity against human 143B cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384172Cytotoxicity against human U2 OS cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1752676Antischistosomal activity against Schistosoma mansoni Liberian NTS incubated for 72 hrs by microscopic method2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID383582Cytotoxicity against human AGS cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383594Cytotoxicity against human BIC1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383579Cytotoxicity against human A549 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID7877Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay2001Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
AID384678Cytotoxicity against human HOS cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384892Cytotoxicity against human KYSE520 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID69714Inhibition of human epidermal growth factor receptor (HER-2) using enzyme assay2001Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
AID384875Cytotoxicity against human KP-1NL cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383391Cytotoxicity against human 273T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384647Cytotoxicity against human NCI-H1623 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384884Cytotoxicity against human KYSE180 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383626Cytotoxicity against human ChaGo-K-1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384189Cytotoxicity against human NCI-H23 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384645Cytotoxicity against human NCI-H1573 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384158Cytotoxicity against human T.T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383902Cytotoxicity against human HCC366 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384375Cytotoxicity against human OE19 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384138Cytotoxicity against human SVts8 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383907Cytotoxicity against human HCC78 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383632Cytotoxicity against human COLO 205 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384680Cytotoxicity against human HRT18 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383892Cytotoxicity against human H69V cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383652Cytotoxicity against human DAN-G cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384868Cytotoxicity against human KHM3S cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384395Cytotoxicity against human PA-TU-8902 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383909Cytotoxicity against human HCE7 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384649Cytotoxicity against human NCI-H1651 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384895Cytotoxicity against human LCLC-103H cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383589Cytotoxicity against human BEAS-2B cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383651Cytotoxicity against human COR-L23 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383580Cytotoxicity against human ABC-1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384161Cytotoxicity against human T47D cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384636Cytotoxicity against human MSTO-211H cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383898Cytotoxicity against human HCC15 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384185Cytotoxicity against human NCI-H2172 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384663Cytotoxicity against human NCI-H2009 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384845Cytotoxicity against human HUP-T4 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383932Cytotoxicity against human SK-BR3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384159Cytotoxicity against human T.Tn cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383389Cytotoxicity against human 201T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384408Cytotoxicity against human RERF-LC-Ad2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383601Cytotoxicity against human BxPC3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384194Cytotoxicity against human NCI-H2452 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383894Cytotoxicity against human HBE135-E6E7 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383899Cytotoxicity against human HCC1806 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384634Cytotoxicity against human MRC9 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384887Cytotoxicity against human KYSE30 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384877Cytotoxicity against human KP3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384390Cytotoxicity against human Panc03.27 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID345876Inhibition of human recombinant EGFR2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies.
AID384876Cytotoxicity against human KP2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384662Cytotoxicity against human NCI-H1975 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384679Cytotoxicity against human HPAC cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384630Cytotoxicity against human MKN7 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384643Cytotoxicity against human NCI-H1563 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383860Cytotoxicity against human DMS 53 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384886Cytotoxicity against human KYSE270 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384389Cytotoxicity against human Panc02.03 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383929Cytotoxicity against human SHP77 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383633Cytotoxicity against human COLO 320DM cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384914Cytotoxicity against human ZR-75-30 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383611Cytotoxicity against human CAL12T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383908Cytotoxicity against human HCC827cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384406Cytotoxicity against human RERF-GC-1B cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384432Cytotoxicity against human LU99C cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384911Cytotoxicity against human YAPC cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384199Cytotoxicity against human NCI-H520 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID260898Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
AID383623Cytotoxicity against human CCF-STTG1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384205Cytotoxicity against human NCI-H727 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384365Cytotoxicity against human NCI-H838 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384146Cytotoxicity against human SW1573 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384433Cytotoxicity against human LUDLU1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384865Cytotoxicity against human KATO II cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384153Cytotoxicity against human SW527 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384878Cytotoxicity against human KP-3L cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383071Inhibition of EGFR L858R/T790M mutant by cellular assay2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID719885Inhibition of EGFR2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Irreversible protein kinase inhibitors: balancing the benefits and risks.
AID384193Cytotoxicity against human NCI-H2444 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384904Cytotoxicity against human WI-38 VA13 sub 2 RA cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384133Cytotoxicity against human SNU5 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384629Cytotoxicity against human MKN45 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384648Cytotoxicity against human NCI-H1650 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID202224Inhibition of cell growth of SW620 cell lines using cell-based assay2001Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
AID1752700Antischistosomal activity against Schistosoma mansoni incubated for 72 hrs by inverted microscopic method2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID384187Cytotoxicity against human NCI-H2228 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384866Cytotoxicity against human KATO III cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383893Cytotoxicity against human HARA cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383620Cytotoxicity against human Capan1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384366Cytotoxicity against human NCI-N87 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384641Cytotoxicity against human NCI-H1435 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383586Cytotoxicity against human AZ521 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383925Cytotoxicity against human SCH cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383904Cytotoxicity against human HCC44 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383922Cytotoxicity against human SBC5 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384666Cytotoxicity against human NCI-H2030 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384644Cytotoxicity against human NCI-H1568 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384853Cytotoxicity against human IMR90 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383390Cytotoxicity against human 23132/87 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384888Cytotoxicity against human KYSE410 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384136Cytotoxicity against human SUIT2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384614Cytotoxicity against human MDA-MB-453 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383889Cytotoxicity against human GTL16 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID202681Inhibition of cell growth of SKBr3 cell lines using cell-based assay2001Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
AID383629Cytotoxicity against human CL34 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384151Cytotoxicity against human SW900 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384204Cytotoxicity against human NCI-H661 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384654Cytotoxicity against human NCI-H1755 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384672Cytotoxicity against human HPAF-II cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383654Cytotoxicity against human DLD1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384437Cytotoxicity against human MCF7 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383649Cytotoxicity against human COR-L 105 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383610Cytotoxicity against human CAL120 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384438Cytotoxicity against human MCF-7/ADR cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384657Cytotoxicity against human NCI-H1793 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384167Cytotoxicity against human TE7 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383859Cytotoxicity against human DMS 273 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384889Cytotoxicity against human KYSE450 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384196Cytotoxicity against human NCI-H358 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1244850Inhibition of epidermal growth factor receptor kinase (unknown origin) using [33P]-ATP after 20 to 30 mins by radiometric assay2015European journal of medicinal chemistry, Sep-18, Volume: 102Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
AID384392Cytotoxicity against human Panc08.13 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383643Cytotoxicity against human SNU16 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384135Cytotoxicity against human SU.86.86 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383577Cytotoxicity against human A427 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384661Cytotoxicity against human NCI-H196 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384651Cytotoxicity against human NCI-H1693 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383619Cytotoxicity against human Calu3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384409Cytotoxicity against human RERF-LC-KJ cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384650Cytotoxicity against human NCI-H1666 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384683Cytotoxicity against human Hs 578T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384852Cytotoxicity against human IM-95m cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384129Cytotoxicity against human SNU1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384682Cytotoxicity against human Hs 417.Lu cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384377Cytotoxicity against human OE33 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384669Cytotoxicity against human NCI-H2087 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384688Cytotoxicity against human Hs 894(E).Lu cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384394Cytotoxicity against human PANC1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384664Cytotoxicity against human NCI-H2023 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383890Cytotoxicity against human H3255 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384398Cytotoxicity against human PC14 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384633Cytotoxicity against human MOG-G-UVW cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383602Cytotoxicity against human C170 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384430Cytotoxicity against human LU99A cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384164Cytotoxicity against human Takigawa cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384637Cytotoxicity against human MT3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384175Cytotoxicity against human UMC11 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383631Cytotoxicity against human COLO 201 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383910Cytotoxicity against human HCT116 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID679514TP_TRANSPORTER: stimulation of ATPase activity (0.1~1 u M) in BCRP-expressing Sf9 cells2004Molecular pharmacology, Jun, Volume: 65, Issue:6
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.
AID383940Cytotoxicity against human SK-MES cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384844Cytotoxicity against human HUP-T3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384894Cytotoxicity against human LC-1 sq cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384191Cytotoxicity against human NCI-H2347 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384147Cytotoxicity against human SW1783 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384861Cytotoxicity against human JIMT1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383866Cytotoxicity against human EFM192A cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383584Cytotoxicity against human AsPC1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1795646Kinase Inhibition Assay from Article 10.1021/jm0005555: \\6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinase2001Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (5.88)18.2507
2000's18 (52.94)29.6817
2010's10 (29.41)24.3611
2020's4 (11.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.98 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.88%)6.00%
Case Studies1 (2.94%)4.05%
Observational0 (0.00%)0.25%
Other31 (91.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]